Works matching IS 20542577 AND DT 2022 AND VI 9 AND IP 3
Results: 13
First-line chemotherapeutic treatment for oligodendroglioma, WHO grade 3—PCV or temozolomide?
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 163, doi. 10.1093/nop/npac023
- By:
- Publication type:
- Article
Forthcoming Meetings.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 251, doi. 10.1093/nop/npac031
- Publication type:
- Article
Primary CNS lymphoma in the real world—Opportunities for improved outcomes in different health settings.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 159, doi. 10.1093/nop/npac028
- By:
- Publication type:
- Article
Treatment of gliomas with temozolomide: Rather at sunrise or sunset?
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 161, doi. 10.1093/nop/npac024
- By:
- Publication type:
- Article
[18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 246, doi. 10.1093/nop/npac021
- By:
- Publication type:
- Article
Neurocognitive function and survival in children with average-risk medulloblastoma treated with hyperfractionated radiation therapy alone: Long-term mature outcomes of a prospective study.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 236, doi. 10.1093/nop/npac020
- By:
- Publication type:
- Article
Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 165, doi. 10.1093/nop/npac015
- By:
- Publication type:
- Article
Impact of neurofibromatosis type 1 in an adult community population.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 229, doi. 10.1093/nop/npac014
- By:
- Publication type:
- Article
Assessing mobility in primary brain tumor patients: A descriptive feasibility study using two established mobility tests.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 219, doi. 10.1093/nop/npac013
- By:
- Publication type:
- Article
Radiation dose to circumscribed brain regions and neurocognitive function in patients with meningioma.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 208, doi. 10.1093/nop/npac011
- By:
- Publication type:
- Article
Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 201, doi. 10.1093/nop/npac004
- By:
- Publication type:
- Article
randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 193, doi. 10.1093/nop/npac003
- By:
- Publication type:
- Article
Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 183, doi. 10.1093/nop/npab066
- By:
- Publication type:
- Article